Day | Untreated control | Lotilaner | Comparison | ||||
---|---|---|---|---|---|---|---|
Mean | Range | Mean | Range | Geometric (arithmetic) mean efficacy (%) | |||
Study 5 | 2 | 18.1 (18.8) | 12–28 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 29.3, P < 0.0001 |
9 | 16.5 (17.8) | 9–29 | 0.1 (0.1) | 0–2 | 99.1 (98.6) | t (7) = 18.4, P < 0.0001 | |
16 | 18.0 (18.6) | 12–24 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 29.1, P < 0.0001 | |
23 | 16.0 (16.4) | 12–23 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 35.6, P < 0.0001 | |
30 | 16.3 (16.5) | 12–20 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 53.3, P < 0.0001 | |
Study 6 | 2 | 19.4 (20.0) | 14–34 | 0.0 (0.0) | 0–0 | 100 (100) | t (9) = 38.8, P < 0.0001 |
9 | 16.2 (17.5) | 5–27 | 0.1 (0.1) | 0–1 | 99.0 (98.9) | t (9) = 18.3, P < 0.0001 | |
16 | 16.9 (18.8) | 5–36 | 0.0 (0.0) | 0–0 | 100 (100) | t (9) = 18.0, P < 0.0001 | |
23 | 18.1 (18.7) | 10–24 | 0.0 (0.0) | 0–0 | 100 (100) | t (9) = 35.0, P < 0.0001 | |
30 | 18.3 (19.3) | 8–27 | 0.0 (0.0) | 0–0 | 100 (100) | t (9) = 26.6, P < 0.0001 |